On the occasion of the ASCO congress (American society of Clinical Cancer), Pr. Eric Raymond has shown the positive results of a worldwide study of immunotherapy for oesophageal cancer. When tislelizumab, a new immunotherapy antibody, is given with the usual chemotherapy, it significantly improves the patient survival with a 34% lower risk of death.
International Patients during the Paris Olympic Games 2024
For an emergency consultation, please go to 189 rue Raymond Losserand, 75014 Paris.